Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies - PubMed
5 days ago
- #acute myeloid leukemia
- #therapy-related AML
- #venetoclax
- Prognosis in therapy-related acute myeloid leukemia (T-AML) remains poor, but venetoclax (VEN)-based therapy shows promise.
- Retrospective analysis of 317 adult patients with newly diagnosed T-AML, excluding those with antecedent myeloid disorders.
- Median age was 69 years; 50% had complex karyotype, 40% had TP53 mutation.
- Composite complete response rates higher with lower intensity therapy (LIT) + VEN vs. LIT alone (58% vs. 40%, P = 0.003).
- Allogeneic hematopoietic stem cell transplantation (HSCT) rates higher in VEN-treated patients.
- Median relapse-free survival (RFS) and overall survival (OS) for full cohort were 7.2 and 8.4 months, respectively.
- In LIT + VEN-treated patients, median RFS and OS were 8.0 and 9.0 months, respectively.
- Patients with ELN2024 favorable risk had median OS of 25.4 months (1-year OS rate of 62%).
- NPM1 and/or IDH mutations associated with 2-year OS over 60%.
- Multivariate analysis in LIT + VEN-treated patients: HSCT and NPM1/IDH2 mutations favorable, TP53/RAS mutations inferior.
- VEN-based therapy improves outcomes in T-AML, especially with VEN-sensitizing genomics and HSCT.